Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Many anemic chronic kidney disease (CKD) patients are refractory to erythropoietin (EPO) effects due to inflammation, deranged iron utilization, and generation of EPO antibodies. This work assessed the effect of desidustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase (PHD), on...

Full description

Bibliographic Details
Main Authors: Amit A. Joharapurkar, Vishal J. Patel, Samadhan G. Kshirsagar, Maulik S. Patel, Hardikkumar H. Savsani, Chetan Kajavadara, Darshan Valani, Mukul R. Jain
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Current Research in Pharmacology and Drug Discovery
Subjects:
EPO resistance
Desidustat
Inflammation
Antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2590257122000220

Internet

http://www.sciencedirect.com/science/article/pii/S2590257122000220

Similar Items